Reimbursed with a limitationOriginator productATC L04AC14

Kevzara

Kevzara is an originator product from Sanofi-Aventis (Suisse) SA and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 1'059.80 to CHF 1'059.80 depending on the pack; the patient co-payment is 10 per cent plus the deductible.

Core data

Authorisation holder
Sanofi-Aventis (Suisse) SA
ATC code
L04AC14
IT group
07.15 Immunosuppressive Stoffe
Active substances
Sarilumabum
Preparation type
Originator product
On the SL since
01/09/2018
Last price change
01/09/2023
Co-payment
10%

Prices per pack

The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.

Kevzara Price table As of 17/09/2026
Dosage formPack sizeEx-factory pricePublic priceValid fromCat.GTIN
Inj Lös 150 mg/1.14 ml Fertigpen2 StkCHF 959.37CHF 1'059.8001/09/2023B7680664250015
Inj Lös 150 mg/1.14 ml Fertigspritze2 StkCHF 959.37CHF 1'059.8001/09/2023B7680664240016
Inj Lös 200 mg/1.14 ml Fertigpen2 StkCHF 959.37CHF 1'059.8001/09/2023B7680664250039
Inj Lös 200 mg/1.14 ml Fertigspritze2 StkCHF 959.37CHF 1'059.8001/09/2023B7680664240030

Limitation

This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.

The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.

FOPH wordingValid from 01/09/2023

Nach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation und Genehmigung des Vertrauensarztes des Krankenversicherers zur Behandlung der aktiven rheumatoiden Arthritis bei erwachsenen Patienten, die auf die Behandlung mit einem konventionellen synthetischen DMARD (disease modifying anti-rheumatic drugs) oder einem Tumornekrosefaktor (TNF)-Hemmer nicht ausreichend angesprochen haben.
Bei einer Unverträglichkeit auf Methotrexat oder wenn die Behandlung mit Methotrexat ungeeignet ist kann Kevzara als Monotherapie verabreicht werden.

FAQ

Is Kevzara covered by Swiss health insurance?

Yes, but only under conditions. Kevzara is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.

What does Kevzara cost in Switzerland?

The public price is the maximum price set by the FOPH and for Kevzara ranges from CHF 1'059.80 to CHF 1'059.80 per pack. The ex-factory price ranges from CHF 959.37 to CHF 959.37. Pharmacies may not charge more, but may charge less.

Correct or complete this entry

Market access

Do you need your product on the Specialities List?

Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.

  • Independent directory
  • Official FOPH data
  • Website in eight languages
Send an enquiry
Contact

About 2 minutes. No obligation.

First, a little about your business.

Your answers stay in this page until you send your enquiry.

What would you like to achieve?

Your project

Where can we reach you?

You can go back to review your answers before sending.

* Required fields
Prefer email? info@swissreimbursement.com